Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Esophageal Cancer Clinical Trials

A listing of Esophageal Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (23) clinical trials

Study of Taladegib in Combination With Weekly Paclitaxel Carboplatin and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction

Study Groups: If you are found to be eligible to take part in this study, you will be assigned to a study group (Phase 1B or Phase 2) based on when you join this study. If you are in Phase 1B, the dose of Taladegib that you will receive is ...

Phase

FLOTOR Pilot Study

The thoracic duct is the largest vessel of the lymphatic system in the body. It transports chyle (a liquid containing both lymph and emulsified fats) from most of the body, including the gastrointestinal tract, into the left internal jugular vein. It is largely located in the thorax and is at ...

Phase

The Study to Evaluate JS001 in Patients With Advanced GC ESCC NPC HNSCC

Overall Design: This is a multicenter, open-label, phase Ib/II clinical study of recombinant humanized anti-programmed death receptor 1 (PD-1) monoclonal antibody for injection (JS001) in patients with gastric adenocarcinoma (GC), esophageal squamous cell carcinoma (ESCC), nasopharyngeal carcinoma (NPC), or head and neck squamous cell carcinoma (HNSCC). On the basis of ...

Phase

A Study of APR-246 in Oesophageal Cancer

Cancer of the oesophagus (OC) is distinguished by having a poor outcome for most patients and an incidence that is rising faster than any other solid cancer. It is already the eighth most common cancer, and the sixth most common cause of death from cancer, worldwide. The majority of patients ...

Phase

Irreversible Electroporation(IRE) For Unresectable Esophageal Neoplasms

By enrolling patients with unresectable Esophageal Neoplasms adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of percutaneous IRE for unresectable Esophageal Neoplasms.

Phase

Combination of Cryosurgery and NK Immunotherapy for Advanced Esophageal Cancer

By enrolling patients with pancreatic cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using cryosurgery and nature killer (NK) cells for advanced esophageal cancer. The safety will be evaluated by statistics of ...

Phase

A Study of Donafenib Monotherapy in Advanced Oesophageal Cancer

This open-label, noncomparative, two-part phase 1B trial recruited patients with advanced, inoperable oesophageal cancer. The primary objectives were to assess the safety for donafenib tosylate tablets .The secondary objectives were to estimate tumor response, progression-free survival, duration of response, and disease control rate (response plus stable disease); to evaluate changes ...

Phase

Combination Margetuximab and Pembrolizumab for Advanced Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer

Detailed Description: Both margetuximab and pembrolizumab are monoclonal antibodies used in combination to treat HER2+ gastric and gastroesophageal junction cancer. This study has two parts: Dose Escalation and Dose Expansion. The Dose Escalation phase of the study will evaluate safety of escalating doses of the combination treatment. The Dose Expansion ...

Phase

Trial of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Cancer

Esophageal carcinoma is the sixth leading cause of cancer-related mortality from cancer with 407000 deaths and the eighth most common cancer worldwide. Concurrent chemoradiotherapy remains the mainstay of treatment for locally advanced esophageal cancer. Paclitaxel combined with radiotherapy was high efficiency and achieved encouraging results. Compared with paclitaxel, nab-paclitaxel has ...

Phase

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

This is an open-label, Phase 1/2 study to evaluate the safety of durvalumab (MEDI4736) in combination with oxaliplatin/capecitabine chemotherapy in metastatic/locally advanced oesophageal cancer (OC) and with neoadjuvant chemo(radio)therapy before surgery in operable OC. The immunotherapy will be given for a 4-week period before starting the standard chemo(radio)therapy, continuing durvalumab ...

Phase